Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.70
Bid: 19.00
Ask: 20.60
Change: 0.00 (0.00%)
Spread: 1.60 (8.421%)
Open: 19.70
High: 0.00
Low: 0.00
Prev. Close: 19.70
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of options

8 Nov 2016 18:25

RNS Number : 6778O
Oncimmune Holdings PLC
08 November 2016
 

8 November 2016

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 8 November 2016, options over ordinary shares of the Company were awarded to certain Directors and certain PDMRs under the Company's 2016 Share Option Plan (an amalgamation of the Company's 2005 and 2007 Share Option Plans) as follows.

 

Name

Position

Number of share options awarded

Option exercise price per share (pence)

Percentage of issued share capital (%)

Meinhard Schmidt

Non-executive Chairman

120,370

108

0.236

Geoffrey Hamilton-Fairley

Chief Executive Officer

528,273

1

1.035

119,875

108

0.235

Andrew Millet

Chief Financial Officer

92,593

108

0.181

Andrea Murray

Chief Operational Scientist

41,667

108

0.082

Maarten Brusse

Chief Commercial Officer

74,074

108

0.145

 

The options are subject to the rules of the 2016 Share Option Plan and vest in five equal annual parts, the first fifth vesting on 7 November 2017 and each year thereafter for a further four years, subject to continued employment. Unless otherwise indicated in the table above, the options are exercisable at 108 pence, being the mid-market closing price of the Company's ordinary shares on 7 November 2016

 

For further information:

 

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

 

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

+44 (0) 203 829 5000

 

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Meinhard Schmidt

2

Reason for the notification

a)

Position/status

 

Non-Executive Chairman, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

120,370

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

120,370

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Geoffrey Hamilton-Fairley

2

Reason for the notification

a)

Position/status

 

Chief Executive Officer

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

528,273

N/A

119.875

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

648,148

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Andrew Millet

2

Reason for the notification

a)

Position/status

 

Chief Financial Officer

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

92,593

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

92,593

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Andrea Murray

2

Reason for the notification

a)

Position/status

 

Chief Operational Scientist and PDMR

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

41,667

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

41,667

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Maarten Brusse

2

Reason for the notification

a)

Position/status

 

Chief Commercial Officer and PDMR

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

74,074

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

74,074

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBIBDBSDGBGLI
Date   Source Headline
28th Apr 20177:00 amRNSFirst Distribution Agreements Signed
24th Apr 20179:18 amRNSGRANT OF OPTIONS
3rd Apr 20177:00 amRNSAppointment of Senior VP, MA & Reimbursement
3rd Apr 20177:00 amRNSGRANT OF OPTIONS AND DEALING BY PDMR
29th Mar 20173:35 pmRNSHolding(s) in Company
10th Feb 20177:00 amRNSInterim Results
8th Feb 20177:00 amRNSNotice of Interim Results
6th Dec 20167:00 amRNSPositive interim data from NHS Screening Trial
30th Nov 20165:47 pmRNSPUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR
30th Nov 201610:47 amRNSResult of Annual General Meeting
8th Nov 20166:25 pmRNSGrant of options
7th Nov 20167:00 amRNSFinal Results
24th Oct 20167:00 amRNSNotice of Full Year Results
11th Oct 20167:00 amRNSBoard Appointment
22nd Sep 20167:00 amRNSAppointment of Chief Commercial Officer Asia
20th Sep 20167:00 amRNSPublication in Journal of Thoracic Oncology
17th Aug 20167:00 amRNSAndrew Millet appointed to the Board as CFO
15th Jul 20167:00 amRNSCE Mark for EarlyCDT®-Lung
4th Jul 20167:00 amRNSResearch Agreements in Ovarian and Liver Cancer
23rd Jun 20161:47 pmRNSBoard Appointment
6th Jun 20162:15 pmRNSDeath of a Director
25th May 20167:00 amRNSOncimmune Signs Three US Distribution Agreements
20th May 20167:00 amRNSHolding(s) in Company
18th May 20167:00 amRNSFirst Day of Dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.